Pre‐Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid‐to‐Late‐Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study

Documenti analoghi

• Long‐Term Outcome of Low‐ and High‐Dose Radioiodine for Thyroid Remnant Ablation
  di: Shiqi Liu, et al.
  Pubblicazione: (2024)
• Brain Metastases in Differentiated Thyroid Carcinoma: Clinical Features, Treatment Outcomes, and the Role of Radioiodine Therapy
  di: Yogita Khandelwal, et al.
  Pubblicazione: (2026)
• Ten Year Outcome of Anti‐Thyroid Drug Treatment for First Episode Graves' Thyrotoxicosis: The Predictive Importance of TRAb
  di: Nyo Nyo Z. Tun, et al.
  Pubblicazione: (2025)
• Thyrotoxicosis due to Gestational Trophoblastic Disease: Unmet Needs in the Management of Gestational Thyrotoxicosis
  di: Kalyan Mansukhbhai Shekhda, et al.
  Pubblicazione: (2024)
• Ethnicity, TSH‐Receptor Antibody (TRAb) and Thyrotoxicosis Severity Are Determinants of Neutrophil Count in Newly Diagnosed Hyperthyroidism
  di: Aman Kaur More, et al.
  Pubblicazione: (2026)